Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO

Attovia Therapeutics Inc. is seeking to raise up to $212.5 million through a US initial public offering. The company develops drugs focused on immune-mediated diseases. Goldman Sachs is among its backers.

Next story